592 related articles for article (PubMed ID: 8363355)
1. Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability.
Wright CI; Geula C; Mesulam MM
Ann Neurol; 1993 Sep; 34(3):373-84. PubMed ID: 8363355
[TBL] [Abstract][Full Text] [Related]
2. Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles.
Eskander MF; Nagykery NG; Leung EY; Khelghati B; Geula C
Brain Res; 2005 Oct; 1060(1-2):144-52. PubMed ID: 16212945
[TBL] [Abstract][Full Text] [Related]
3. Protease inhibitors and indolamines selectively inhibit cholinesterases in the histopathologic structures of Alzheimer's disease.
Wright CI; Geula C; Mesulam MM
Ann N Y Acad Sci; 1993 Sep; 695():65-8. PubMed ID: 8239315
[TBL] [Abstract][Full Text] [Related]
4. Anatomy of cholinesterase inhibition in Alzheimer's disease: effect of physostigmine and tetrahydroaminoacridine on plaques and tangles.
Mesulam MM; Geula C; Morán MA
Ann Neurol; 1987 Dec; 22(6):683-91. PubMed ID: 3435078
[TBL] [Abstract][Full Text] [Related]
5. Differential laminar distribution of acetylcholinesterase and butyrylcholinesterase containing tangles in the cerebral cortex of Alzheimer's disease.
Coleman AE; Geula C; Price BH; Mesulam MM
Brain Res; 1992 Nov; 596(1-2):340-4. PubMed ID: 1467998
[TBL] [Abstract][Full Text] [Related]
6. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
Pacheco G; Palacios-Esquivel R; Moss DE
J Pharmacol Exp Ther; 1995 Aug; 274(2):767-70. PubMed ID: 7636741
[TBL] [Abstract][Full Text] [Related]
7. Cholinesterases in normal and Alzheimer's disease primary olfactory gyrus.
Hamodat H; Cash MK; Fisk JD; Darvesh S
Neuropathol Appl Neurobiol; 2017 Dec; 43(7):571-583. PubMed ID: 28644906
[TBL] [Abstract][Full Text] [Related]
8. Immunocytochemical characterization of glial fibrillary tangles in Alzheimer's disease brain.
Nishimura M; Tomimoto H; Suenaga T; Namba Y; Ikeda K; Akiguchi I; Kimura J
Am J Pathol; 1995 May; 146(5):1052-8. PubMed ID: 7747799
[TBL] [Abstract][Full Text] [Related]
9. In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses.
Kuhl DE; Koeppe RA; Snyder SE; Minoshima S; Frey KA; Kilbourn MR
Ann Neurol; 2006 Jan; 59(1):13-20. PubMed ID: 16278840
[TBL] [Abstract][Full Text] [Related]
10. Cholinesterases within neurofibrillary tangles related to age and Alzheimer's disease.
Mesulam MM; Asuncion Morán M
Ann Neurol; 1987 Aug; 22(2):223-8. PubMed ID: 3662453
[TBL] [Abstract][Full Text] [Related]
11. Cholinergic innervation of the amygdaloid complex in the human brain and its alterations in old age and Alzheimer's disease.
Emre M; Heckers S; Mash DC; Geula C; Mesulam MM
J Comp Neurol; 1993 Oct; 336(1):117-34. PubMed ID: 8254109
[TBL] [Abstract][Full Text] [Related]
12. Brain cholinesterases: I. The clinico-histopathological and biochemical basis of Alzheimer's disease.
Shen ZX
Med Hypotheses; 2004; 63(2):285-97. PubMed ID: 15236793
[TBL] [Abstract][Full Text] [Related]
13. A quantitative study of neurofibrillary tangles, senile plaques and astrocytes in the hippocampal subdivisions and entorhinal cortex in Alzheimer's disease, normal controls and non-Alzheimer neuropsychiatric diseases.
Muramori F; Kobayashi K; Nakamura I
Psychiatry Clin Neurosci; 1998 Dec; 52(6):593-9. PubMed ID: 9895207
[TBL] [Abstract][Full Text] [Related]
14. The neuropathological changes associated with normal brain aging.
Hof PR; Glannakopoulos P; Bouras C
Histol Histopathol; 1996 Oct; 11(4):1075-88. PubMed ID: 8930649
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
Duysen EG; Li B; Darvesh S; Lockridge O
Toxicology; 2007 Apr; 233(1-3):60-9. PubMed ID: 17194517
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of two different cholinesterases by tacrine.
Ahmed M; Rocha JB; Corrêa M; Mazzanti CM; Zanin RF; Morsch AL; Morsch VM; Schetinger MR
Chem Biol Interact; 2006 Aug; 162(2):165-71. PubMed ID: 16860785
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical analysis of hippocampal butyrylcholinesterase: Implications for regional vulnerability in Alzheimer's disease.
Mizukami K; Akatsu H; Abrahamson EE; Mi Z; Ikonomovic MD
Neuropathology; 2016 Apr; 36(2):135-45. PubMed ID: 26293308
[TBL] [Abstract][Full Text] [Related]
18. A peptidyl-prolyl isomerase, FKBP12, accumulates in Alzheimer neurofibrillary tangles.
Sugata H; Matsuo K; Nakagawa T; Takahashi M; Mukai H; Ono Y; Maeda K; Akiyama H; Kawamata T
Neurosci Lett; 2009 Aug; 459(2):96-9. PubMed ID: 19414059
[TBL] [Abstract][Full Text] [Related]
19. [A comparative study on histopathological findings between Alzheimer's disease and senile dementia of Alzheimer type].
Nakamura N
Rinsho Byori; 1996 Mar; 44(3):225-30. PubMed ID: 8857164
[TBL] [Abstract][Full Text] [Related]
20. Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease.
Kung MP; Hou C; Zhuang ZP; Skovronsky D; Kung HF
Brain Res; 2004 Oct; 1025(1-2):98-105. PubMed ID: 15464749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
